Serum resistin levels in patients with type 2 diabetes mellitus and its relationship with glycosylated hemoglobin
Paper Details
Serum resistin levels in patients with type 2 diabetes mellitus and its relationship with glycosylated hemoglobin
Abstract
To compare serum resistin levels in type 2 diabetic patients (T2DM) and normal controls and to assess the relationship between serum resistin level and glycosylated hemoglobin (HbA1c) in type 2 diabetic patients. The study comprised of two groups i.e. Group A and Group B. Group A consisted of 100 diabetic patients and group B consisted of 100 healthy individuals (control). Blood samples were taken and analyzed for serum resistin, fasting blood glucose (FBG) and glycosylated hemoglobin. SPSS version 19 was used to analyze the data obtained. The values were stated as mean±SD. Assessment of relationship between resistin and HbA1c was done through Pearson’s correlation co-efficient. Type 2 diabetic patients showed significantly higher level of resistin as compared to the normal control (30.4+8.50 vs. 18.9+2.31, p = <0.05).The diabetic group manifested significantly higher values of HbA1c (8.5+1.73 vs. 4.0+0.76) and FBG (158.5+28.30 vs. 84.9+20.01). Serum resistin levels showed a strong positive association (p < 0.001) with glycosylated hemoglobin (r .816) in the diabetic group through Pearson’s correlation co-efficient r. Type 2 DM patients have significantly higher resistin levels than healthy individuals which is positively correlated with fasting blood sugar and HbA1csupporting the evidence that resistin plays an important role in the pathogenesis of insulin resistance which could indirectly contribute to the development of type 2 DM.
American Diabetes Association. Standards of medical care in diabetes – 2010. Diabetes Care. 2010; 33Suppl 1:S11–61. http://dx.doi.org/10.2337/dc10-S011
Azab N, Abdel-Aziz T, Ahmed A, El-deen IM. 2016. Correlation of serum resistin level with insulin resistance and severity of retinopathy in type 2 diabetes mellitus. Journal of Saudi Chemical Society 20(3), 272-7.
Barnes KM, Miner JL. 2009. Role of resistin in insulin sensitivity in rodents and humans. Current Protein and Peptide Science 10(1), 96-107.
Bonora E, Tuomilehto J. 2011. The pros and cons of diagnosing diabetes with A1C. Diabetes care 34, 184-90.
Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. 2006. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. The Journal of Clinical Endocrinology & Metabolism 91(1), 64-8.
Gharibeh MY, Al Tawallbeh GM, Abboud MM, Radaideh A, Alhader AA, Khabour OF. 2010. Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes & metabolism 36(6), 443-9.
Gokhale NH, Acharya AB, Patil VS, Trivedi DJ, Setty S, Thakur SL. 2014. Resistin levels in gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus. Journal of periodontology 85(4), 610-7.
He ZL, Chen Y, Ma J, Yu WH, Li YY, Yang FM, Wang JB, Chen LX, Zhao Y, Lu SY. 2015. Relevance and clinical significance of serum resistin level in obese T2DM rhesus monkey models. Experimental and Clinical Endocrinology & Diabetes 123(08), 508-13.
Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz PE, Del Bosque-Plata L. 2000. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nature genetics 26(2), 163.
Huang X, Yang Z. 2016. Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans. Journal of endocrinological investigation 39(6), 607-15.
Cho NH, Shaw JE, Karuranga S, Huang Y, Rocha Fernandes JD da, Ohlrogge AW, Malanda B. 2018. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice 138, 271-281. https://doi.org/10.1016/j.diabres.2018.02.023
Jamaluddin MS, Weakly SM, Yao Q, Chen C. 2012. Resistin: Functional role and therapeutic considerations for cardiovascular disease. British Journal of Pharmacology 165, 622-32.
Pajunen P, Peltonen M, Eriksson JG, Ilanne‐Parikka P, Aunola S, Keinänen‐Kiukaanniemi S, Uusitupa M, Tuomilehto J, Lindström J. 2011. Finnish Diabetes Prevention Study (DPS). HbA1c in diagnosing and predicting type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetic Medicine 28(1), 36-42.
Shiv Narayan Lahariya, Purnima Dey Sarkar, Sunil Dwived. 2015. Role of adipokines in periodontal disease with diabetes mellitus and without diabetes mellitus International Journal of Biological and Medical Research 6(3), 5078-5081.
Steppan CM, Lazar MA. 2004. Current biology of resistin. Journal of Internal Medicine 255, 439-47.
Uslu S, Kebapçı N, Kara M, Bal C. 2012 Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Experimental and therapeutic medicine 4(1), 113-20.
Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver Wr Jr, Willson TM, Kliewer SA, Hotamisligil GS. 2001. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator activated receptor gamma agonists. The Journal of Biological Chemistry 276(28), 25651–3.
(WHO). 2016. World Health Organization, Diabetes profile
Zaidi SI, Shirwany TA. 2015. Relationship of serum resistin with insulin resistance and obesity. Journal of Ayub Medical College Abbottabad 27(3), 552-5.
Maheen Saad, Fatima Ehsan, Kirn-e-Muneera, Muhammad Adnan Saeed, Sobia Ali, Hafsa Aziz, 2019. Serum resistin levels in patients with type 2 diabetes mellitus and its relationship with glycosylated hemoglobin. Int. J. Biosci., 15(4), 312-317.
Copyright © 2019 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.